Hepatitis B Virus (HBV) Capsid Inhibitors Global Market Report 2025

The hepatitis B virus (HBV) capsid inhibitors market size has grown rapidly in recent years. It will grow from $0.46 billion in 2024 to $0.52 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period resulted from increasing clinical trials focused on HBV capsid assembly modulators, the rising inclusion of HBV in national immunization and health surveillance programs, growing publication of clinical data validating capsid inhibitor efficacy, heightened global awareness campaigns promoting HBV prevention and management, and the increasing adoption of advanced molecular modeling and drug design technologies.

The hepatitis B virus (HBV) capsid inhibitors market size is expected to see rapid growth in the next few years. It will grow to $0.86 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period will be driven by rising demand for combination therapies, an increasing number of pipeline products entering advanced clinical trial phases, higher patient awareness and screening rates for chronic HBV infection, growing adoption of personalized treatment approaches targeting viral resistance, and expanding use of digital platforms for clinical monitoring and treatment adherence. Major trends in the forecast period include the advancement of next-generation capsid assembly modulators progressing through clinical trials, development of advanced combination regimens pairing capsid inhibitors with immune modulators and cccDNA-targeting agents, innovative oral small-molecule formulations designed to improve patient adherence, integration of biomarkers and companion diagnostics to guide therapy selection, and progress in strategies for managing and preventing resistance, including next-generation molecules.

The rising prevalence of hepatitis B virus (HBV) infections is expected to drive the growth of the hepatitis B virus (HBV) capsid inhibitors market. Hepatitis B virus (HBV) infections are liver infections caused by the hepatitis B virus, which can lead to both acute and chronic diseases. The virus spreads through contact with infected blood or bodily fluids and can result in serious complications such as liver cirrhosis or liver cancer. The increasing prevalence of HBV infections is largely attributed to low vaccination coverage, leaving significant portions of the population unprotected and facilitating virus transmission. HBV capsid inhibitors aid in treating hepatitis B infections by disrupting the formation and assembly of the viral capsid, thereby preventing viral replication and reducing the spread of infection within the body. For example, in April 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that as of the end of 2022, only 13% of individuals with chronic hepatitis B had been diagnosed, and approximately 3% (7 million) had received antiviral treatment. In comparison, for hepatitis C, 36% of affected individuals had been diagnosed, with 20% (12.5 million) receiving curative therapy, figures well below the global target of treating 80% of people living with chronic hepatitis B and C by 2030. Therefore, the increasing prevalence of hepatitis B virus infections is driving the growth of the HBV capsid inhibitors market.

Major companies operating in the HBV capsid inhibitors market are focusing on developing advancements such as oral small-molecule capsid assembly modulators to improve antiviral efficacy, patient compliance, and achieve sustained viral suppression. Oral small-molecule capsid assembly modulators are orally administered antiviral agents that interfere with the assembly of the hepatitis B virus capsid, blocking replication and reducing viral activity in the body. For instance, in July 2024, Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical company, collaborated with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical company, to launch a clinical trial evaluating innovative treatment candidates for chronic hepatitis B (CHB). The trial leverages advanced capsid assembly modulator technology to enhance antiviral efficacy and accelerate the development of next-generation HBV therapies, marking a significant step in Aligos’s mission to develop effective and potentially curative treatments for chronic hepatitis B patients.

In October 2023, Gilead Sciences Inc., a US-based biopharmaceutical company, partnered with Assembly Biosciences Inc. to combine its antiviral expertise with Assembly Biosciences’ innovative capsid inhibitor technology. The collaboration aims to accelerate the development of next-generation small-molecule antivirals that enhance viral suppression, improve treatment outcomes, and potentially achieve a functional cure for patients living with chronic hepatitis B infection. Assembly Biosciences Inc., based in the US, specializes in the discovery and development of antiviral therapeutics, including novel agents targeting hepatitis B virus and other viral infections.

Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.

Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2024. The regions covered in hepatitis B virus (HBV) capsid inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hepatitis B virus (HBV) capsid inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The hepatitis B virus (HBV) capsid inhibitors market research report is one of a series of new reports that provides hepatitis B virus (HBV) capsid inhibitors market statistics, including hepatitis B virus (HBV) capsid inhibitors industry global market size, regional shares, competitors with a hepatitis B virus (HBV) capsid inhibitors market share, detailed hepatitis B virus (HBV) capsid inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis B virus (HBV) capsid inhibitors industry. This hepatitis B virus (HBV) capsid inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hepatitis B virus (HBV) capsid inhibitors are antiviral agents designed to interfere with the assembly, disassembly, or stability of the viral capsid, which is crucial for HBV replication. These inhibitors act on the core protein that forms the protective shell around the viral DNA, thereby preventing the creation of new infectious particles. By disrupting the capsid formation process, they help lower viral load and slow disease progression. HBV capsid inhibitors represent a promising therapeutic strategy for moving toward a functional cure for chronic hepatitis B infection.

The main drug types of hepatitis B virus (HBV) capsid inhibitors include core protein allosteric modulators (CpAMs), capsid assembly modulators, and others. HBV capsid inhibitors, also known as core protein allosteric modulators (CpAMs), are antiviral agents that target and disrupt capsid assembly or stability, thereby blocking HBV replication and decreasing viral activity. The applications include chronic hepatitis B, acute hepatitis B, and other related uses, and they are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels. End users include hospitals, clinics, research institutes, and other healthcare settings.

The hepatitis B virus (HBV) capsid inhibitors market consists of sales of vebicorvir, bepirovirsen, cavrotolimod, hepcludex, and morphothiadin. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.